Skip to main content
Premium Trial:

Request an Annual Quote

Alnylam Seals $330M RNAi IP Deal, $42.5M Investment with Roche

NEW YORK (GenomeWeb News) - Alnylam Pharmaceuticals said yesterday that it has closed its previously announced strategic alliance with Roche under which Roche agreed to license an Alnylam RNAi therapeutic technology platform and certain intellectual property, acquire one of Alnylam’s labs, and work with the firm on drug-discovery projects.
Under the agreement, Roche will make aggregate payments to Alnylam of around $331 million, including an upfront cash payment within ten business days of the closing in connection with the license.
In addition, the Roche Venture Fund has purchased 1.975 million shares of Alnylam common stock for a total of $42.5 million.
Roche also closed the purchase of an Alnylam lab in Kulmbach, Germany, for an undisclosed sum.
GenomeWeb Daily News sister publication RNAi News reported last month that Alnylam will have to pay around $30 million to other partners, primarily Isis Pharmaceuticals, from which it has licensed IP covered under the Roche deal.

The Scan

Booster Push

New data shows a decline in SARS-CoV-2 vaccine efficacy over time, which the New York Times says Pfizer is using to argue its case for a booster, even as the lower efficacy remains high.

With Help from Mr. Fluffington, PurrhD

Cats could make good study animals for genetic research, the University of Missouri's Leslie Lyons tells the Atlantic.

Man Charged With Threatening to Harm Fauci, Collins

The Hill reports that Thomas Patrick Connally, Jr., was charged with making threats against federal officials.

Nature Papers Present Approach to Find Natural Products, Method to ID Cancer Driver Mutations, More

In Nature this week: combination of cryogenic electron microscopy with genome mining helps uncover natural products, driver mutations in cancer, and more.